March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the ...

Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET "The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can ...

The drug, a once-daily pill called Vykat XR, was developed by Soleno Therapeutics. “The approval of Vykat XR is a significant milestone for Soleno and, most importantly, for the PWS community ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the ...

A source familiar with the situation told the Business Journal that the executive team and board of directors at Lyndra Therapeutics resigned on Tuesday. Lyndra Therapeutics, a drug developer that ...

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. Feel unsure about the ...

HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...